INDIANAPOLIS (AP) _ A panel of European regulators have recommended against approving antidepressant Cymbalta as a treatment for the pain disorder fibromyalgia, drugmaker Eli Lilly and Co. said Friday.
The "negative opinion" comes from the Committee for Medicinal Products for Human Use, which makes recommendations to the European Medicines Agency based on clinical data. The drug is Eli Lilly's second biggest seller and is used to treat depression, anxiety, and diabetic nerve pain.
Fibromyalgia is a chronic pain disorder.
The Food and Drug Administration approved Cymbalta as a treatment for fibromyalgia in June. Eli Lilly and its European partner, Boehringer Ingelheim, said there are no approved fibromyalgia treatments in the European Union.